CompletedNot Applicable

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

United States259 participantsStarted 2012-02-20

Plain-language summary

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease (GVHD).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are receiving allogeneic stem cell transplantation at the Ohio State University Blood and Marrow Transplantation program are eligible and will be consented for the study.

What they're measuring

Measure miR-155 expression levels over time in the serum from patients receiving allogeneic stem cell transplant, and evaluate if miR-155 expression can predict development of aGVHD (Acute Graft-versus-Host Disease)

Timeframe: up to 14 weeks

Trial details

NCT IDNCT01521039

SponsorOhio State University Comprehensive Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-30

View on ClinicalTrials.gov More Acute Graft-versus-Host Disease trials